Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy
- PMID: 36947131
- DOI: 10.1093/cid/ciad168
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy
Abstract
Background: In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs).
Methods: Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated.
Results: A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%-100%. For moxifloxacin and rifampicin, the PTAs were 71%-100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%-17%.Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics.
Conclusions: For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis.
Keywords: infective endocarditis; oral antibiotics; pharmacodynamics; pharmacokinetics; target attainment.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. C. T. P. reports a grant from Bayer for a randomized study, and a grant from Novo Nordisk for an epidemiological study. L. K. reports payment for speaking engagements from AstraZeneca, Bayer, Boehringer, and Novartis. C. M. reports payment for speaking engagements from AstraZeneca, GSK, MSD, and Pfizer; co-authorship of the Danish Treatment Guidelines for Infective Endocarditis and of the ESCMID guidelines for prevention, treatment and diagnosis of biofilm infections; and service as a board member of the European Society for Clinical Microbiology Study Group (ESCMID) for Biofilms (ESGB). E. L. F. reports grants from Novo Nordisk Foundation and the Danish Heart Association. N. E. B. reports grants from Novo Nordisk Foundation, Health Insurance Denmark, and Augustinus Foundation (all unrelated to this study). F. S. R. reports unpaid positions on the Danish Ministry of Health's National expert advisory board on antimicrobial stewardship, the Region of Southern Denmark's Regional working group on antimicrobial stewardship, and chairman on the Steering committee and working group at Odense University Hospital for rational use of antimicrobial drugs. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Target attainment of benzylpenicillin in patients with infective endocarditis.Clin Microbiol Infect. 2025 Aug;31(8):1350-1355. doi: 10.1016/j.cmi.2025.04.025. Epub 2025 Apr 28. Clin Microbiol Infect. 2025. PMID: 40306489 Clinical Trial.
-
Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.J Antimicrob Chemother. 2023 Dec 1;78(12):2840-2848. doi: 10.1093/jac/dkad316. J Antimicrob Chemother. 2023. PMID: 37823408
-
Impact of susceptibility to antibiotics of streptococci & enterococci isolated from patients with infective endocarditis on antibiotic treatment.Indian J Med Res. 2004 May;119 Suppl:80-3. Indian J Med Res. 2004. PMID: 15232168
-
Oral antibiotics for infective endocarditis: a clinical review.J Antimicrob Chemother. 2020 Aug 1;75(8):2021-2027. doi: 10.1093/jac/dkaa106. J Antimicrob Chemother. 2020. PMID: 32240296 Review.
-
A comparison of different antibiotic regimens for the treatment of infective endocarditis.Cochrane Database Syst Rev. 2020 May 14;5(5):CD009880. doi: 10.1002/14651858.CD009880.pub3. Cochrane Database Syst Rev. 2020. PMID: 32407558 Free PMC article.
Cited by
-
Transcatheter aortic valve implantation (TAVI) prostheses in vitro - biofilm formation and antibiotic effects.Biofilm. 2024 Nov 1;8:100236. doi: 10.1016/j.bioflm.2024.100236. eCollection 2024 Dec. Biofilm. 2024. PMID: 39555138 Free PMC article.
-
Plasma Concentrations of Benzylpenicillin and Cloxacillin in Infective Endocarditis-With Special Reference to Delayed Hypersensitivity Reactions.Antibiotics (Basel). 2025 Jan 9;14(1):56. doi: 10.3390/antibiotics14010056. Antibiotics (Basel). 2025. PMID: 39858342 Free PMC article.
-
Staphylococcus aureus vertebral osteomyelitis: a single-centre retrospective cohort study with focus on oral flucloxacillin follow-up.Eur J Clin Microbiol Infect Dis. 2025 May 28. doi: 10.1007/s10096-025-05176-8. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40434591
-
A Multicenter Retrospective Study Evaluating Intravenous to Oral Antibiotic Stepdown for Uncomplicated Streptococcal Bacteremia.Open Forum Infect Dis. 2024 Jun 28;11(7):ofae361. doi: 10.1093/ofid/ofae361. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38975249 Free PMC article.
-
Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives.Microorganisms. 2023 Dec 18;11(12):3004. doi: 10.3390/microorganisms11123004. Microorganisms. 2023. PMID: 38138148 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical